Reports Q3 revenue $104.6M, consensus $104.57M. “In the third quarter, we continued to make good progress towards our full-year revenue and profitability targets,” said William Feehery, CEO. “We recently launched several new software products, including Certara (CERT)IQ for QSP modeling, which we believe will expand the use of biosimulation technology in drug development. We remain focused on investing in our R&D and commercial efforts to position Certara for sustainable, long-term growth.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT: